Trials / Completed
CompletedNCT03856619
To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis
A Single Arm Phase IV Clinical Trial to Describe the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary Objective: To describe the safety of teriflunomide in patients with relapsing forms of multiple sclerosis. Secondary Objective: To describe the efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis.
Detailed description
The study duration is one year; post treatment safety follow up visit will be conducted 4 weeks after the patient takes the last dose of teriflunomide
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TERIFLUNOMIDE HMR1726 | Pharmaceutical form: Tablet Route of administration: Oral |
Timeline
- Start date
- 2019-03-27
- Primary completion
- 2022-05-13
- Completion
- 2022-05-13
- First posted
- 2019-02-27
- Last updated
- 2023-04-19
Locations
14 sites across 1 country: India
Source: ClinicalTrials.gov record NCT03856619. Inclusion in this directory is not an endorsement.